Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

Abstract Background The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSCT) promotes hematopoiesis by inducin...

Full description

Bibliographic Details
Main Authors: Michael M. B. Green, Nelson Chao, Saurabh Chhabra, Kelly Corbet, Cristina Gasparetto, Ari Horwitz, Zhiguo Li, Jagadish Kummetha Venkata, Gwynn Long, Alice Mims, David Rizzieri, Stefanie Sarantopoulos, Robert Stuart, Anthony D. Sung, Keith M. Sullivan, Luciano Costa, Mitchell Horwitz, Yubin Kang
Format: Article
Language:English
Published: BMC 2016-08-01
Series:Journal of Hematology & Oncology
Subjects:
CXCR4
Antagonist
Stromal-derived factor-1
Hematopoietic stem cell transplantation
Hematopoietic stem cells
Outcomes
Online Access:http://link.springer.com/article/10.1186/s13045-016-0301-2

Internet

http://link.springer.com/article/10.1186/s13045-016-0301-2

Similar Items